SMTL ID : 6n3l.1 (1 other biounit)

Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.61 Å

Oligo State

monomer

Ligands

1 x KAV: N-{6-[(1-methyl-2-{[4-(trifluoromethyl)phenyl]amino}-1H-benzimidazol-5-yl)oxy]pyrimidin-4-yl}cyclopropanecarboxamide(Non-covalent)

KAV.1: 24 residues within 4Å: Chain A: L.36, V.44, A.57, K.59, E.76, L.80, L.83, I.88, V.89, I.117, M.119, E.120, Y.121, C.122, A.124, T.126, I.156, M.161, H.163, F.172, I.181, G.182, D.183, F.184 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:L.36, A:V.44, A:L.80, A:Y.121, A:T.126, A:D.183, A:F.184 Hydrogen bonds: A:E.76, A:E.76, A:C.122, A:C.122, A:D.183 pi-Stacking: A:F.172

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Fujimoto, J. et al., Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Acs Med.Chem.Lett. (2019)

Release Date

2019-10-09

Peptides

eIF-2-alpha kinase GCN2,eIF-2-alpha kinase GCN2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

eIF-2-alpha kinase GCN2,eIF-2-alpha kinase GCN2

Related Entries With Identical Sequence